Basecamp Research, a biotechnology startup focused on artificial intelligence, has raised $60 million in funding and signed a multi-year collaboration with the Broad Institute of MIT and Harvard.

Basecamp Research是一家专注于人工智能的生物技术初创公司，已筹集6000万美元资金，并与麻省理工学院和哈佛大学布罗德研究所（Broad Institute of MIT）签署了多年合作协议。

The London-based company said Wednesday that it will work with the lab of David Liu, a prominent gene editing researcher and biotech entrepreneur, to advance new types of “programmable” genetic medicines. The collaboration aims to invent “novel fusion proteins and other large molecules” that might enable those medicines, it said in a statement.

这家总部位于伦敦的公司周三表示，将与著名的基因编辑研究员和生物技术企业家David Liu的实验室合作，推进新型“可编程”基因药物。它在一份声明中表示，该合作旨在发明“新型融合蛋白和其他大分子”，可能使这些药物成为可能。

Basecamp did not provide specifics..

Basecamp没有提供细节。。

The collaboration and funding are steps forward for Basecamp, one of many biotech startups trying to capitalize on the promise of AI in aiding pharmaceutical research. AI has been the focus of many recent industry partnerships, as its proponents believe the technology can make drug discovery more efficient.

Basecamp是众多试图利用人工智能在帮助药物研究方面的承诺的生物技术初创公司之一，合作和资金是Basecamp向前迈出的一步。人工智能一直是最近许多行业合作伙伴的焦点，因为其支持者认为该技术可以提高药物发现的效率。

While there have been computing breakthroughs in areas like predicting how proteins change shape, AI’s broader potential in drugmaking hasn’t yet been fulfilled..

虽然在预测蛋白质如何改变形状等领域取得了计算机突破，但人工智能在制药领域的更广泛潜力尚未实现。。

Basecamp is developing a database of biological interactions found in nature and using it to give artificial intelligence models more detailed training in biology. Basecamp intends this work to help with a variety of areas of research, from drugs and diagnostics to agriculture. The company has partnerships with 15 companies working in biological science, three of which are with large drugmakers, said CEO and co-founder Glen Gowers..

。Basecamp打算开展这项工作，以帮助开展从药物和诊断到农业的各种研究领域。首席执行官兼联合创始人格伦·高尔斯（GlenGowers）表示，该公司与15家从事生物科学的公司建立了合作关系，其中三家与大型制药商合作。。

Basecamp says its database is larger than what’s publicly available to other researchers. Its executives also contend its approach is broader than that of most AI drug discovery companies, which, Gowers claims, are training AI by running a series of scientific experiments. That’s a 'fundamentally quite archaic way of looking at AI,' he argues, because it limits what the technology can learn..

Basecamp表示，它的数据库比其他研究人员公开获得的数据库要大。其高管还认为，其方法比大多数人工智能药物发现公司的方法更为广泛，高尔斯声称，这些公司正在通过进行一系列科学实验来训练人工智能。他认为，这是一种“从根本上看人工智能非常古老的方式”，因为它限制了技术可以学习的东西。。

'AI is not magic,' he said. 'It's a pattern recognition tool that has creativity, but within the limits of what it's already seen.'

“AI不是魔法，”他说这是一种具有创造力的模式识别工具，但在它已经看到的范围内。”

In gene editing, drug researchers could benefit from a detailed look at the constant “warfare” between bacteria and viruses, Gowers said. Basecamp has been compiling data on the “weapons” used in those microscopic battles, which could be a resource to help uncover new gene editing approaches, he said..

高尔斯说，在基因编辑方面，药物研究人员可以从细菌和病毒之间持续不断的“战争”中受益。他说，Basecamp一直在收集这些微观战争中使用的“武器”的数据，这可能是帮助发现新的基因编辑方法的资源。。

Liu’s lab will use that information, though Gowers didn’t reveal details beyond the company’s announcement.

刘的实验室将使用这些信息，尽管高尔斯没有透露公司声明之外的细节。

Basecamp’s Series B round was led by Paris-based venture firm Singular and backed by a number of life sciences and tech investors, including S32, Roche vice chairman André Hoffmann and former Unilever CEO Paul Polman. It has now raised $85 million since starting in 2019, and earlier this year hired Anupama Hoey, a former business development executive at biotechs Sutro Biopharma and Second Genome, as its chief commercial officer..

Basecamp的B轮由总部位于巴黎的风险投资公司Singular牵头，并得到了许多生命科学和技术投资者的支持，包括S32、罗氏副董事长安德烈·霍夫曼和联合利华前首席执行官保罗·波尔曼。自2019年成立以来，该公司现已筹资8500万美元，今年早些时候，该公司聘请了生物技术公司Sutro Biopharma和第二基因组公司（Second Genome）前业务发展主管阿努帕玛·霍伊（Anupama Hoey）担任首席商务官。。

“Basecamp has dedicated itself to solving some of the toughest challenges in the life sciences and is taking a truly first principles approach to address questions that the biopharma industry hasn’t even known to ask,” Andy Conrad, a general partner at S32 and the founder of Alphabet’s Verily Life Sciences, said in a statement..

S32的普通合伙人、Alphabet的Verily life sciences创始人安迪·康拉德（AndyConrad）在一份声明中表示：“Basecamp致力于解决生命科学领域的一些最严峻挑战，并正在采取真正的第一原则方法来解决生物制药行业甚至不知道要问的问题。”。。

Basecamp will use new funding to continue building its database in the hopes of working with a “wider range” of biopharma companies, Gowers said.

高尔斯表示，Basecamp将利用新资金继续建设其数据库，以期与“更广泛”的生物制药公司合作。